NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam's Appointment of Bryan Humbarger as Chief Commercial Officer and Company Overview
TL;DR
HeartBeam appoints Bryan Humbarger as CCO to drive commercial strategy for its FDA-cleared 3D ECG system, potentially gaining market advantage in portable cardiac monitoring.
HeartBeam's system uses cable-free 3D ECG technology to synthesize 12-lead data, enabling arrhythmia assessment and heart attack detection through a wearable patch monitor.
This technology allows cardiac monitoring outside medical facilities, improving early detection and care access to enhance patient outcomes and cardiac health management.
HeartBeam's FDA-cleared device captures 3D ECG signals from three directions, creating the first portable system for comprehensive heart monitoring anywhere.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam (NASDAQ: BEAT) has appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026, to lead commercial strategy and execution for the company's cardiac monitoring technology.
Bryan Humbarger is the newly appointed Chief Commercial Officer at HeartBeam who will lead commercial strategy and execution across key growth initiatives, including the limited launch of the HeartBeam System and expanding outreach to cardiology partners.
HeartBeam creates the first-ever cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance in December 2025.
The technology is designed for arrhythmia assessment, heart attack detection, and as a 12-lead ECG extended wear patch monitor, allowing physicians to identify cardiac health trends and acute conditions outside medical facilities.
Detailed information about the intended use of HeartBeam's technology can be found in the Company's Cleared Indications for Use at https://www.heartbeam.com/indications.
The full press release is available at https://ibn.fm/9YzeT, and the latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
This appointment supports HeartBeam's commercial strategy for launching its FDA-cleared technology, expanding outreach to cardiology partners, validating real-world performance, and establishing reference sites for broader adoption.
The content contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ, and investors should review the company's SEC filings, particularly the 'Risk Factors' sections, and not place undue reliance on these statements.
Curated from NewMediaWire
